Webinar

A Toxicologist's Viewpoint On Developing Oncology Drug Products

With oncology growth rates on the rise, pharma companies are pressured to develop and manufacture life-saving therapies with speed and agility. Cancer growth rates are driven by environmental factors, lifestyle choices, and an aging population. Approximately 42% of the oncology market pipeline is attributed to oral solid doses.* Since oncology drugs are commonly categorized as highly potent, they require various handling and safety strategies.

In this webinar, toxicologist Joe Galati discusses:

  • Criteria for evaluating highly potent small molecules
  • Toxicity banding systems
  • Downgrading a molecule from high potent to low potent:
  • Safety and handling strategies

*Source: IQVIA- Global MIDAS Edition Includes antineoplastic agents (L01) and endocrine therapy (L02)- 248 molecules, OSD includes: tablets, ODT, capsules

VIEW THE WEBINAR!
Signing up provides unlimited access to:
Signing up provides unlimited access to:
  • Trend and Leadership Articles
  • Case Studies
  • Extensive Product Database
  • Premium Content
HELLO. PLEASE LOG IN. X

Not yet a member of Outsourced Pharma? Register today.

ACCOUNT SIGN UP X
Please fill in your account details
Login Information
ACCOUNT SIGN UP

Subscriptions

Sign up for the newsletter that brings you the industry's latest news, technologies, trends and products.

You might also want to: